Nodular basal cell carcinoma is associated with increased hyaluronan homeostasis

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 6, 2011, Pages 679-687

  Tzellos, T G ^a   Kyrgidis, A ^b   Vahtsevanos, K ^b   Triaridis, S ^a   Printza, A ^a   Klagas, I ^a   Zvintzou, E ^a   Kritis, A ^a   Karakiulakis, G ^a   Papakonstantinou, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Theagenion Anti Cancer Hospital   (Greece)

Author keywords

basal cell carcinoma; CD44; hyaluronan; hyaluronan synthases; hyaluronidases; RHAMM

Indexed keywords

BETA ACTIN; CD44V ANTIGEN; CHONDROITIN 4 SULFATE; CHONDROITIN ABC LYASE; CHONDROITIN SULFATE; CHONDROITINASE B; DERMATAN SULFATE; ENZYME; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN G1; GLYCOSAMINOGLYCAN G2; GLYCOSAMINOGLYCAN G3; GLYCOSAMINOGLYCAN G4; HEPARAN SULFATE; HEPARIN; HEPARIN LYASE; HEPARITINASE; HYALURONIC ACID; HYALURONIC ACID SYNTHASE; HYALURONIC ACID SYNTHASE 1; HYALURONIC ACID SYNTHASE 2; HYALURONIC ACID SYNTHASE 3; HYALURONIDASE; HYALURONIDASE 1; HYALURONIDASE 2; HYALURONIDASE 3; KERATAN SULFATE; KERATANASE; RECEPTOR; RECEPTOR HYALURONIC ACID MEDIATED MOTILITY; UNCLASSIFIED DRUG;

AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE; FEMALE; GENE EXPRESSION; GLYCOSAMINOGLYCAN METABOLISM; HAS3 GENE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYAL3 GENE; MALE; NODULAR BASAL CELL CARCINOMA; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHAMM GENE; UPREGULATION;

AGED; ANTIGENS, CD44; CARCINOMA, BASAL CELL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HOMEOSTASIS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MALE; MIDDLE AGED; SKIN NEOPLASMS; UP-REGULATION;

EID: 79955882041     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03851.x     Document Type: Article

References (76)

1. Rippey JJ,. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-398. (Pubitemid 28231370)
2. Giles GG, Marks R, Foley P,. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J 1998; 296: 13-17.
3. Bertheim U, Hofer PA, Engstrom-Laurent A, Hellstrom S,. The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy. Br J Plast Surg 2004; 57: 429-439. (Pubitemid 38842752)
4. Conley J, Sachs ME, Romo T, et al. Metastatic basal cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1985; 93: 78-85. (Pubitemid 16115803)
5. Kyrgidis A, Vahtsevanos K, Tzellos TG, et al. Clinical, histological and demographic predictors for recurrence and second primary tumour of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital. Eur J Dermatol 2010; 20: 276-282.
6. Sexton M, Jones DB, Maloney ME,. Histologic pattern analysis of basal cell carcinoma. J Am Acad Dermatol 1990; 23: 1118-1126.
7. Kyrgidis A, Tzellos TG, Vahtsevanos K, Triaridis S,. New concepts for basal cell carcinoma Demographic, clinical, histological risk factors and biomarkers. A systematic review of evidence regarding risk for tumour development, susceptibility for second primary and recurrence. J Surg Res 2010; 159: 545-556.
8. Yu M, Zloty D, Cowan B, et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 2008; 128: 1797-1805. (Pubitemid 351847372)
9. Manuskiatti W, Maibach HI,. Hyaluronic acid and skin: wound healing and aging. Int J Derm 1996; 35: 539-544. (Pubitemid 26261919)
10. Laurent TC, Fraser JR,. Hyaluronan. FASEB J. 1992; 6: 2397-2404.
11. Papakonstantinou E, Karakiulakis G, Roth M, Effects of hypoxia on glycosaminoglycan synthesis by lung cells. In, Garg HG, Roughley PJ, Hales CA, eds. Proteoglycans and Lung Disease, Series Vol 168:. Lung Biology in Health and Disease. Marcel Dekker, New York, 2002.
12. Tolg C, Hamilton SR, Nakrieko KA, et al. Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 2006; 175: 1017-1028. (Pubitemid 44969206)
13. Hamilton SR, Fard SF, Paiwand FF, et al. The Hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282: 16667-16680. (Pubitemid 47100370)
14. Rudrabhatla SR, Mahaffey CL, Mummert ME,. Tumor microenvironment modulates hyaluronan expression: The Lactate effect. J Invest Dermatol 2006; 126: 1378-1387. (Pubitemid 43997922)
15. Papakonstantinou E, Karakiulakis G, Eickelberg O, et al. A 340-kDa hyaluronic acid secreted by human vascular smooth muscle cells regulates their proliferation and migration. Glycobiology 1998; 8: 821-830. (Pubitemid 28356854)
16. Turley EA,. Hyaluronan and cell locomotion. Cancer Metastasis Rev 1992; 11: 21-30.
17. Toole BP,. Developmental role of hyaluronate. Connect Tissue Res 1982; 10: 93-100. (Pubitemid 12018703)
18. Auvinen PK, Parkkinen JJ, Johansson RT, et al. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997; 74: 477-481. (Pubitemid 27486503)
19. Ropponen K, Tammi M, Parkkinen J, et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-347. (Pubitemid 28047077)
20. Weigel PH, DeAngelis PL,. Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J Biol Chem 2007; 282: 36777-36781.
21. Weigel PH, Hascall VC, Tammi M,. Hyaluronan synthases. J Biol Chem 1997; 272: 13997-14000. (Pubitemid 27232793)
22. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 25085-25092.
23. Bertrand P, Girard N, Duval C, et al. Increased hyaluronidase levels in breast tumor metastasis. Int J Cancer 1997; 73: 327-331. (Pubitemid 27508893)
24. Csoka AB, Scherer SW, Stern R,. Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 1999; 60: 356-361. (Pubitemid 29471502)
25. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y,. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-579. (Pubitemid 35425379)
26. Navolanic PM, Steelman LS, McCubrey JA,. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 2003; 22: 237-252.
27. Bourguignon LY, Singleton PA, Zhu H, Zhou B,. Hyaluronan promotes signalling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 2002; 277: 39703-39712. (Pubitemid 35190953)
28. Toole BP,. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-539. (Pubitemid 38868622)
29. Dingemans KP, Ramkema MD, Pals ST,. CD44 is exposed to the extracellular matrix at invasive sites in basal cell carcinomas. Lab Invest 2002; 82: 313-322. (Pubitemid 34242525)
30. Dingemans KP, Ramkema MD, Koopman G, et al. The expression of CD44 glycoprotein adhesion molecules in basal cell carcinomas is related to growth pattern and invasiveness. Br J Dermatol 1999; 140: 17-25. (Pubitemid 29074526)
31. Joukov V, Groen AC, Prokhorova T, et al. The BRCA1/BARD1 heterodimer modulates randependen mitotic spindle assembly. Cell 2006; 127: 539-552. (Pubitemid 44647427)
32. Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995; 82: 19-26.
33. Nedvetzki S, Gonen E, Assayag N, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004; 101: 18081-18086. (Pubitemid 40054077)
34. Tolg C, Poon R, Fodde R, et al. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 2003; 22: 6873-6882. (Pubitemid 37386687)
35. Zaman A, Cui Z, Foley JP, et al. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol 2005; 33: 447-454. (Pubitemid 41572687)
36. Tzellos TG, Klagas I, Vahtsevanos K, et al. Extrinsic ageing in the human skin is associated with alterations in the expression of hyaluronic acid and its metabolizing enzymes. Exp Dermatol 2009; 18: 1028-1035.
37. Goulas A, Hatzichristou DG, Karakiulakis G, et al. Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate 2000; 44: 104-110. (Pubitemid 30419184)
38. Bitter T, Muir H,. A modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-334.
39. Goulas A, Papakonstantinou E, Karakiulakis G, et al. Tissue structure-specific distribution of glycosaminoglycans in the human penis. Int J Biochem Cell Biol 2000; 32: 975-982.
40. Sugahara K, Mikami T, Uyama T, et al. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol 2003; 13: 612-620. (Pubitemid 37244117)
41. Sugahara K, Mikami T,. Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol 2007; 17: 536-545. (Pubitemid 350019013)
42. Iida J, Meijne AM, Knutson JR, et al. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 1996; 7: 155-162. (Pubitemid 26179262)
43. Malavaki C, Mizumoto S, Karamanos N, Sugahara K,. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 2008; 49: 133-139.
44. Nikitovic D, Assouti M, Sifaki M, et al. Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int J Biochem Cell Biol 2008; 40: 72-83. (Pubitemid 350052660)
45. Li F, Ten Dam GB, Murugan S, et al. Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J Biol Chem 2008; 283: 34294-34304.
46. Rollins BJ, Culp LA,. Glycosaminoglycans in the substrate adhesion sites of normal and virus transformed murine cells. Biochemistry 1979; 18: 141-148. (Pubitemid 9094213)
47. Zimmermann DR, Dours-Zimmermann MT, Schubert M, Bruckner-Tuderman L,. Versican is expressed in the proliferation zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994; 124: 817-825. (Pubitemid 24085789)
48. Karvinen S, Kosma VM, Tammi MI, Tammi R,. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol 2003; 148: 86-94. (Pubitemid 36114867)
49. Moy RL, Potter TS, Uitto J,. Increased glycosaminoglycans production in sclerosing basal cell carcinoma-derived fibroblasts and stimulation of normal skin fibroblast glycosaminoglycans production by a cytokine-derived from sclerosing basal cell carcinoma. Dermatol Surg 2000; 26: 1029-1034.
50. Parrott JA, Nilssen E, Mosher R, et al. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumour stromal cells. Mol Endocrinol 2001; 175: 29-39. (Pubitemid 32372541)
51. Knudson W, Biswas C, Li XQ, et al. The role and regulation of tumour-associated hyaluronan. Ciba Found Symp 1989; 143: 150-159.
52. Anttila MA, Tammi RH, Tammi MI, et al. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150-155. (Pubitemid 30058745)
53. Toole B,. Glycosaminoglycans in morphogenesis. In, Hay ED, ed. Cell Biology of the Extracellular Matrix. Plenum Press, New York, 1981: 259-294.
54. Rooney P, Kumar S, Ponting J, Wang M,. The role of hyaluronan in tumour neovascularization. Int J Cancer 1995; 60: 632-636.
55. Pollack SV, Goslen JB, Sherertz EF, Jegasothy BV,. The biology of basal cell carcinoma: a review. J Am Acad Dermatol 1982; 7: 569-577. (Pubitemid 12000522)
56. Averbeck M, Gebhardt CA, Voigt S, et al. Differential regulation of hyaluronan metabolism in the epidermal and dermal compartments of human skin by UVB irradiation. J Invest Dermatol 2007; 127: 687-697.
57. Harada H, Takahashi M,. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007; 282: 5597-5607. (Pubitemid 47093756)
58. Hemming R, Martin DC, Slominski E, et al. Mouse Hyal3 encodes a 45-56 kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells. Glycobiology 2008; 18: 280-289. (Pubitemid 351461061)
59. Chao KL, Muthukumar L, Herzberg O,. Structure of human Hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis. Biochemistry 2007; 46: 6911-6920. (Pubitemid 46906420)
60. Poole AR, Dieppe P,. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994; 23: 17-31. (Pubitemid 24189753)
61. Voelcker V, Gebhardt C, Averbeck M, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008; 17: 100-107.
62. Ohkawara Y, Tamura G, Iwasaki T, et al. Activation and transforming growth factor-beta production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol 2000; 23: 444-451.
63. Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666. (Pubitemid 39062729)
64. Gambichler T, Skrygan M, Kaczmarczyk JM, et al. Increased expression of TGF-beta/Smad proteins in basal cell carcinoma. Eur J Med Res 2007; 12: 509-514. (Pubitemid 350110853)
65. Dvorak HF,. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659. (Pubitemid 17052899)
66. Dingemans KP, Zeeman-Boeschoten IM, Keep RF, Das PK,. Transplantation of colon carcinoma into granulation tissue induces an invasive morphotype. Int J Cancer 1993; 54: 1010-1016. (Pubitemid 23267478)
67. Stern R, Maibach HI,. Hyaluronan in skin: aspects of aging and its pharmacologic modulation. Clin Dermatol 2008; 26: 106-122. (Pubitemid 351620989)
68. Guttinger M, Sutti F, Barnier C, et al. Expression of CD44 standard and variant forms in skin tumors. Loss of CD44 correlates with aggressive potential. Eur J Dermatol 1995; 5: 398-406.
69. Prieto VG, Reed JA, McNutt NS, et al. Differential expression of CD44 in malignant cutaneous epithelial neoplasms. Am J Dermatopathol 1995; 17: 447-451.
70. Seiter S, Tilgen W, Herrmann K, et al. Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch 1996; 428: 141-149. (Pubitemid 26237444)
71. Hale LP, Dhavalkumar DP, Clark RE, Haynes BF,. Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. J Cutan Pathol 1995; 22: 536-545. (Pubitemid 26013710)
72. Seelentag WKF, Gunthert U, Saremaslani P, et al. CD44 standard and variant isoform expression in human epidermal skin tumors is not correlated with tumor aggressiveness but down-regulated during proliferation and tumor de-differentiation. Int J Cancer 1996; 69: 218-224. (Pubitemid 26233302)
73. Hodge-Dufour J, Noble PW, Horton MR, et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol 1997; 159: 2492-2500. (Pubitemid 127681045)
74. Yu Q, Stamenkovic I,. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Devel 1999; 13: 35-48. (Pubitemid 29045114)
75. Yu Q, Stamenkovic I,. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Devel 2000; 14: 163-176. (Pubitemid 30070982)
76. Tzellos TG, Klagas I, Papakonstantinou E, et al. Differential expression of matrix metalloproteinases 2 and 9 in basal cell carcinoma, photo-exposed and photo-protected skin. Rev Clin Pharmacol Pharmacokinet 2008; 22: 358-359. (Pubitemid 351831306)